Clinical trial
Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity…
NCT00419445 · CoMentis, Industry · Completed
Key facts
| NCT number | NCT00419445 |
|---|---|
| Title | Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder |
| Official title | A Double-Blind, Randomized, Proof-of-Concept Crossover Trial to Assess the Effects of GTS21 on Cognitive Function, Clinical Symptoms, and Adverse Events in Adults Diagnosed With Attention-Deficit Hyperactivity Disorder |
| Lead sponsor | CoMentis, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | GTS21/Placebo |
| Enrollment | 37 |
| Start date | Feb 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Jan 8, 2007 |
| Last update posted | Sep 10, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: